Novartis on course to set new highs

20/02/24 -"Considering the strong operational performance and a meaningful progress for the late-stage pipeline in recent years, we have revised upwards our NAV estimates by c.10%."

Executive summary
Conflict of interest

Pages

Language

English

Published on

20/02/24

Download

You may also be interested by these reports :

07/07/26

Sanofi

Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...

06/07/26

Ipsen

Our target price has been adjusted downward as we have removed the 20% premium associated with peer-based valuation metrics. This adjustment is due ...

30/06/26

Bayer

The recent US Supreme Court decision in the Roundup litigations, went in favour of Bayer, and brings the firm very close to ending this chapter. Even ...

24/06/26

Bachem , PolyPeptide

Rather than trying to figure out who will win the obesity race, why not bet on more defensive upstream API production?

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue